A medical device, on occasion, can spawn a new specialty. A clever engineer designs a device or implant small enough to be deployed by those skilled with a guidewire and catheter, enabling an interventionalist to reach an organ previously accessible only through surgery. Over the past decades, these advances have helped minimize the physical impact of treating a blocked artery, fractured vertebrae or a dangerous spot of cancer. Neuronetics Inc. is an unlikely contributor to this movement. The nine-year-old neurostimulation company created a device capable of safely reaching one of the most remote areas of the body – the brain. And, in doing so, the company created a new specialty of sorts, one that carries a somewhat contradictory tag – the interventional psychiatrist.
Neuronetics Brightens Outlook For Neuro Devices
Neuronetics Inc. forged a new specialty of sorts, the interventional psychiatrist. Unlike other interventional approaches, the externally applied NeuroStar delivers transcranial magnetic stimulation to the precise area of the brain responsible for intractable depression. The device is changing the lives of psychiatrists who launched “TMS” clinics, hoping to capture the early success, and potentially creating opportunities for medical devices designed to treat other brain-related disorders.
More from Business Strategy
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Licensing deals have been growing in popularity over outright acquisitions in the pharmaceutical industry over the past decade. Licensing deals have doubled in number from 2015 to 2024, while M&A activity has decreased post-COVID. We consider the advantages of licensing deals and review notable licensing deals from the past 10 years with the potential to deliver high value relative to their initial investment.
More from In Vivo
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
Lundbeck CEO Charl van Zyl spoke with In Vivo about the Danish company’s multipronged transformation, one that involves a rethink of company culture, pipeline strategy and a sharpened focus on innovation in rare neurological disorders.